← Eichor
Condition: Undiagnosed Diseases Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Undiagnosed Diseases

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Early Diagnosis and Treatment of Undiagnosed Asthma or COPD: THE UCAP 2 TRIAL
NA · 4 location(s) · Ottawa Hospital Research Institute · NCT06392776Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
Phase N/A · 33 location(s) · National Human Genome Research Institute (NHGRI) · NCT02450851Gait and Balance Impairment in Rare and Very Rare Neurological Diseases
Phase N/A · 2 location(s) · Istituto Auxologico Italiano · NCT06343558Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-m
Phase N/A · 1 location(s) · ZS Associates · NCT06866483#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-i
NA · 28 location(s) · Casper Rokx · NCT06900829Gene Discovery Core, The Manton Center
Phase N/A · 1 location(s) · Boston Children's Hospital · NCT02743845Diagnostic Odyssey: Whole Genome Sequencing (WGS)
Phase N/A · 1 location(s) · Nicklaus Children's Hospital f/k/a Miami Children's Hospital · NCT03458962Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.
Phase 4 · 1 location(s) · Well- Konnect Healthcare Services and Research Firm · NCT06441955Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168Exome and Genome Analysis to Elucidate Genetic Etiologies and Population Characteristics in the Plain Community
Phase N/A · 1 location(s) · University of Pittsburgh · NCT02927158Our Healthbox - Evaluating Interactive Dispensing Systems for Low-Barrier Access to HIV Testing and Harm Reduction.
NA · 1 location(s) · Unity Health Toronto · NCT05516069Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
NA · 1 location(s) · Mario Negri Institute for Pharmacological Research · NCT05996731Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
NA · 1 location(s) · University of Texas Southwestern Medical Center · NCT06593314Vascular Disease Discovery Protocol
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT03538639UW Undiagnosed Genetic Diseases Program
Phase N/A · 1 location(s) · University of Wisconsin, Madison · NCT04586075Caregiving Networks Across Disease Context and the Life Course
Phase N/A · 1 location(s) · National Human Genome Research Institute (NHGRI) · NCT05007990Genetic Analysis of Uncommon Disease Presentations in Non-US Populations
Phase N/A · 1 location(s) · National Human Genome Research Institute (NHGRI) · NCT06595940Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT02543996Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
Phase N/A · 1 location(s) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT04880356Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT01487603
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.